In vivo therapeutic synergy of SAR650984, a humanized anti-CD38 antibody, in combination with melphalan in a multiple myeloma xenograft.

被引：0
作者：
Lejeune, Pascale
Blanc, Veronique
Courta, Jacqueline
Egile, Coumaran
Vrignaud, Patricia
Deckert, Jutta
Park, Peter
Bissery, Marie-Christine
机构：
[1] Sanofi Aventis, Vitry Sur Seine, France
[2] ImmunoGen Inc, Waltham, MA USA
来源：
CANCER RESEARCH | 2009年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2797
引用
收藏
页数：1
相关论文
共 50 条
  • [31] The effects of anti-CD38 monoclonal antibody and anti-HI antibody on pretransfusion testing in a patient with multiple myeloma
    Zhu, Zhe
    Hong, Kairui
    Ke, Yefang
    ANNALS OF HEMATOLOGY, 2023, 102 (07) : 1961 - 1962
  • [32] Combination of Melphalan Flufenamide and Anti-PD-L1 or Anti-CD38 Antibodies Enhances Anti-Myeloma Immunity
    Ray, Arghya
    Du, Ting
    Nupponen, Nina N.
    Lehmann, Fredrik
    Lindberg, Jakob
    Gullbo, Joachim
    Richardson, Paul G.
    Chauhan, Dharminder
    Anderson, Kenneth C.
    BLOOD, 2021, 138
  • [33] A combination of humanized anti-BCMA and murine anti-CD38 CAR-T cell therapy in patients with relapsed or refractory multiple myeloma
    Zhang, Huan
    Liu, Man
    Xiao, Xia
    Lv, Hairong
    Jiang, Yanyu
    Li, Xin
    Yuan, Ting
    Zhao, Mingfeng
    LEUKEMIA & LYMPHOMA, 2022, 63 (06) : 1418 - 1427
  • [34] Improved Myeloma Targeting by Combination of the Human Anti-CD38 Antibody Daratumumab with Lenalidomide and Bortezomib.
    van der Veer, Michael S.
    de Weers, Michel
    van Kessel, Berris
    Bakker, Joost M.
    Wittebol, Shulamiet
    Parren, Paul W. H. I.
    Lokhorst, Henk M.
    Mutis, Tuna
    BLOOD, 2010, 116 (21) : 1249 - 1249
  • [35] SAR442085, a next generation anti-CD38 antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC) against multiple myeloma
    Virone-Oddos, Angela
    Kassem, Sahar
    Diallo, Bere
    Tang, Alexandre
    Fournier, Alain
    El-Murr, Nizar
    Carrie-Constantin, Nadege
    Nicolazzi, Celine
    Arnould, Isabelle
    Avet-Loiseau, Herve
    Sidhu, Sukhvinder S.
    Martinet, Ludovic
    Chiron, Marielle
    CANCER RESEARCH, 2020, 80 (16)
  • [36] A phase lb dose escalation trial of isatuximab (SAR650984, anti-CD38 mAb) plus lenalidomide and dexamethasone (Len/Dex) in relapsed/refractory multiple myeloma (RRMM): Interim results from two new dose cohorts.
    Vij, Ravi
    Lendvai, Nikoletta
    Martin, Thomas G.
    Baz, Rachid C.
    Campana, Frank
    Mazuir, Florent
    Charpentier, Eric
    Benson, Don M.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [37] ANALYSIS OF THE USE OF THE ANTI-CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA FROM OUR CENTER
    Pimentel, Villar M. A.
    Anguita, Arance M. M.
    Almagro, Torres F.
    Lopez, Lopez J. A.
    HAEMATOLOGICA, 2021, 106 (10) : 337 - 337
  • [38] Effects of Soluble and MicrovesicleBound Therapeutic Anti-CD38 Antibodies on Immune Effector Cells in Multiple Myeloma
    Faini, Angelo Corso
    Castella, Barbara
    Horenstein, Alberto
    Morandi, Fabio
    Malavasi, Fabio
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S418 - S418
  • [39] Determinants of Response to Anti-CD38 and Bispecific Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma
    Aleman, Adolfo
    Zajdman, Ariel Kogan
    Mouhieddine, Tarek
    Upadhyaya, Bhaskar
    Van Oekelen, Oliver
    Lagana, Alessandro
    Grossman, Leah
    Thibaud, Santiago
    Sanchez, Larysa
    Richard, Shambavi
    Rossi, Adriana
    Richter, Joshua
    Cho, Hearn Jay
    Rodriguez-Valdes, Cesar
    Chari, Ajai
    Parekh, Samir
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S41 - S41
  • [40] Effects of Soluble and MicrovesicleBound Therapeutic Anti-CD38 Antibodies on Immune Effector Cells in Multiple Myeloma
    Oses, Lucrecia
    Brulc, Erika
    Carretero, Marcelina
    Nucifora, Elsa
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S418 - S418
12345